沙夫肼盐酸盐 | 7296-30-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 中文名称: 沙夫肼盐酸盐
• 中文别名: 盐酸沙夫肼
• 英文名称: safrazine
• 英文别名: (4-(benzo[d][1,3]dioxol-5-yl)butan-2-yl)hydrazine hydrochloride；safrazine hydrochloride；4-(1,3-benzodioxol-5-yl)butan-2-ylhydrazine;hydrochloride
• CAS: 7296-30-2
• 化学式: C₁₁H₁₆N₂O₂*ClH
• mdl: MFCD01722404
• 分子量: 244.721
• InChiKey: UOZNXVYMTZITGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.69
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  58.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-(benzo[d][1,3]dioxol-5-yl)butan-2-ol 、 偶氮二甲酸二叔丁酯 在 三苯基膦 、 乙酰氯 、 盐酸 作用下， 以 乙腈 、 甲醇 、 水 为溶剂， 以66 %的产率得到沙夫肼盐酸盐
  参考文献：
  名称：

  醇类肼衍生物的实用流程合成

  摘要：

  在此，我们展示了连续流动技术在通过游离醇与二叔丁基偶氮二甲酸酯脱氧合成肼衍生物中的应用。这种操作简单的协议具有出色的功能组耐受性，可实现大规模合成和后期功能化。它还提供了对三个药理化合物家族的访问。

  DOI：

  10.1039/d3nj02065g

文献信息

• BICYCLIC HETEROCYCLIC COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1961745A1

  公开（公告）日：2008-08-27

  A compound represented by the formula (I), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof: wherein X, Y, and W each independently represent a carbon atom or a nitrogen atom; Z represents CH or a nitrogen atom; R1 represents (1) C3-10 branched alkyl which may be substituted or (2) -(CH2)m-NR4R5; R2 and R3 each independently represent (1) a hydrogen atom, (2) C1-4 alkyl which may be substituted with a halogen atom, hydroxy which may be protected, amino which may be protected, or carboxyl which may be protected, (3) C2-4 alkenyl, (4) C2-4 alkynyl, (5) nitrile, (6) COOR6, (7) CONR7R8, (8) COR101, (9) S(O)nR102, or (10) a halogen atom, in which R6 represents a hydrogen atom or C1-4 alkyl, R7 and R8 each independently represent a hydrogen atom or C1-4 alkyl, R101 represents a hydrogen atom or C1-4 alkyl, R102 represents C1-4 alkyl, n represents 1 or 2; and Ar represents an aromatic ring which may be substituted, is useful as a pharmacologically active ingredient having a CRF antagonist action in preventing and/or treating neuropsychiatric diseases, diseases of peripheral organs or the like.

  公式（I）表示的化合物，其盐，其N-氧化物，其溶剂合物或其前药：其中X，Y和W分别独立表示碳原子或氮原子；Z表示CH或氮原子；R1表示（1）可能被取代的C3-10支链烷基或（2）-(CH2)m-NR4R5；R2和R3分别独立表示（1）氢原子，（2）可能被卤原子取代的C1-4烷基，可能被保护的羟基，可能被保护的氨基，或可能被保护的羧基，（3）C2-4烯基，（4）C2-4炔基，（5）腈基，（6）COOR6，（7）CONR7R8，（8）COR101，（9）S（O）nR102，或（10）卤原子，其中R6表示氢原子或C1-4烷基，R7和R8分别独立表示氢原子或C1-4烷基，R101表示氢原子或C1-4烷基，R102表示C1-4烷基，n表示1或2；Ar表示可能被取代的芳香环，用作在预防和/或治疗神经精神疾病，外周器官疾病等方面具有CRF拮抗作用的药理活性成分。
• THERAPEUTIC AGENT FOR PSYCHONEUROTIC DISEASE
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1787657A1

  公开（公告）日：2007-05-23

  The present invention relates to a preventive and/or therapeutic agent for psychoneurotic diseases, comprising an EP3 antagonist represented by the general formula (I): (wherein the meanings of characters are defined in the description). This compound has an antagonistic potency against EP3 and exhibits efficacy through unusual action mechanism as a preventive and/or therapeutic agent for psychoneurotic disorder, psychosomatic disorder, anxiety disorder, depression and disorder caused by stress.

  本发明涉及一种预防和/或治疗心神经疾病的药剂，包括一种由一般公式(I)表示的EP3拮抗剂：（其中字符的含义在描述中定义）。该化合物具有对EP3的拮抗作用，通过不寻常的作用机制作为一种预防和/或治疗心神经紊乱、心身疾病、焦虑症、抑郁症以及由压力引起的疾病的药剂展现出疗效。
• ACID-ADDITION SALT OF Trk-INHIBITING COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20170240527A1

  公开（公告）日：2017-08-24

  In order to provide a prophylactic and/or therapeutic agent for Trk-related diseases, the present invention provides a compound which has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and in addition thereto, is excellent in solubility and absorbability against free bases. The compound of the present invention has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and is excellent in solubility and absorbability against free bases, and is therefore useful as a prophylactic and/or therapeutic agent for Trk-related diseases.

  为了为Trk相关疾病提供一种预防和/或治疗剂，本发明提供了一种具有选择性Trk抑制活性的化合物，持续抑制NGF血管高渗透性，并且不具有药物相互作用，此外，该化合物在溶解性和对游离碱的吸收性方面表现出色。本发明的化合物具有选择性Trk抑制活性，持续抑制NGF血管高渗透性，不具有药物相互作用，在溶解性和对游离碱的吸收性方面表现出色，因此可作为Trk相关疾病的预防和/或治疗剂。
• Crf antagonists and heterobicyclic compounds
  申请人：Nakai Hisao

  公开号：US20070027156A1

  公开（公告）日：2007-02-01

  CRF antagonists comprising as an active ingredient, the compound of formula (I) wherein A ring is 5-6 membered mono-cyclic ring which may be substituted; B ring is 5-7 membered unsaturated mono-heterocyclic ring which may be contained another 1-2 of hetero atom(s) and substituted by another substituents; W 1 and W 2 is carbon atom or nitrogen atom; Z is NR 3 , oxygen atom, sulfur which may be oxidized or CR 4 R 5 ; R 1 is alkyl, alkenyl or alkynyl that may be substituted, amino which may be protected, hydroxyl which may be protected, S(O) n R 6 , COR 7 , or cyclic group which may be substituted; R 2 is unsaturated cyclic group which may be substituted.

  CRF拮抗剂包括化合物(I)作为活性成分，其中A环是5-6成员单环，可以被取代；B环是5-7成员不饱和单杂环，可能包含另外1-2个杂原子，并被另外的取代基取代；W1和W2是碳原子或氮原子；Z是NR3、氧原子、硫，可以被氧化或CR4R5取代；R1是烷基、烯基或炔基，可以被取代，氨基可以被保护，羟基可以被保护，S（O）nR6、COR7或环状基团可以被取代；R2是不饱和环状基团，可以被取代。
• Therapeutic agent for psychoneurotic disease
  申请人：Narita Masami

  公开号：US20090286862A1

  公开（公告）日：2009-11-19

  The present invention relates to a preventive and/or therapeutic agent for psychoneurotic diseases, comprising an EP 3 antagonist represented by the general formula (I): (wherein the meanings of characters are defined in the description). This compound has an antagonistic potency against EP 3 and exhibits efficacy through unusual action mechanism as a preventive and/or therapeutic agent for psychoneurotic disorder, psychosomatic disorder, anxiety disorder, depression and disorder caused by stress.

  本发明涉及一种预防和/或治疗精神神经疾病的药剂，其包括一种由通式（I）表示的EP3拮抗剂：（其中字符的含义在描述中定义）。该化合物具有对EP3的拮抗效力，并通过不寻常的作用机制表现出作为预防和/或治疗精神神经障碍、心身障碍、焦虑症、抑郁症和由压力引起的障碍的药剂的功效。